Lanbote
Nanjing pet pharmaceuticals — companion-animal drug R&D, GMP manufacturing and hospital-channel sales
About Lanbote
Lanbote (南京朗博特动物药业有限公司; brand Lanbote / 朗博特) is a Nanjing-based companion-animal pharmaceutical company focused on R&D, GMP manufacturing, sales and service of pet medicines—not a generic livestock-drug wholesaler. It operates a ~2,000 m² pet-drug R&D centre and a ~12,000 m² manufacturing base with multiple veterinary GMP lines (eye/ear drops, ointments, tablets, oral solutions, disinfectants, ectoparasiticides).
The company reports dozens of patents and new veterinary drug certificates, deep cooperation with thousands of pet hospitals, and retail reach to hundreds of thousands of pet owners. Public coverage and filings describe angel (2018) and Series A (2019) rounds with investors including Renai, Lichen, Furong Capital, Yunpu and Jinpu, plus later investor additions (e.g. Zhuopu / Yingmeng). It was listed among Nanjing’s cultivated unicorn/gazelle cohort.
Lanbote positions itself as an innovation-driven pet health (companion animal) pharma player serving China’s growing pet-hospital channel, distinct from large livestock animal-health groups.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.3/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Aug 2024 | — | — | CICC | ↗ |
| SERIES B✓Equity / VC | Jul 2023 | $14M | $55M | Innomed Capital · Shanghai Zhuopu Investment | ↗ |
Growth signals
Latest recorded traffic for Lanbote is 110 monthly website visits, down 79.2% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lanbote in the Nanjing City ecosystem
The Lanbote office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- ICInnomed Capital
Shanghai Zhuopu Investment
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lanbote on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lanbote’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.
